Onco Filtration has developed a proprietary filtration technology that processes over 12,000 milliliters of whole blood to effectively remove circulating tumor cells (CTCs), significantly enhancing the capacity for cancer diagnostics and treatment. This advancement addresses the critical need for improved methods in managing solid tumors, which affect over 100 million people globally each year.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for detecting and analyzing circulating tumor cells (CTCs) in blood samples process limited volumes, hindering comprehensive cancer diagnostics and treatment monitoring. Existing technologies typically analyze less than 10 milliliters of blood, potentially missing critical information about the tumor's characteristics and behavior.
Solution
Onco Filtration has developed a filtration technology designed to process over 12,000 milliliters of whole blood, significantly increasing the capture of circulating tumor cells (CTCs). By processing a larger volume of blood, the technology enhances the ability to detect and analyze CTCs, providing a more complete picture of the tumor's presence and characteristics. This improved CTC capture rate opens new possibilities for cancer diagnostics, treatment monitoring, and personalized medicine approaches. The technology aims to improve the management of solid tumors, which affect a significant portion of the global population.
Target Audience
The primary audience includes oncologists, cancer researchers, and diagnostic laboratories seeking improved methods for CTC detection and analysis.
Features
- Proprietary filtration technology capable of processing large volumes of whole blood (over 12,000 mL).
- Enhanced capture rate of circulating tumor cells (CTCs) compared to traditional methods.
- Potential for improved cancer diagnostics and treatment monitoring.